Pharmacotechnical Development of a Nasal Drug Delivery Composite Nanosystem Intended for Alzheimer's Disease Treatment

Overview

Journal Pharmaceutics

Publisher MDPI

Date 2020 Mar 15

PMID 32168767

Citations 17

Authors

Thomas Adnet

Anne-Claire Groo

Celine Picard

Audrey Davis

Sophie Corvaisier

Marc Since

Frederic Bounoure

Christophe Rochais

Loic Le Pluart

Patrick Dallemagne

Aurelie Malzert-Freon

Affiliations

Soon will be listed here.

Abstract

Direct nose-to-brain delivery has been raised as a non-invasive powerful strategy to deliver drugs to the brain bypassing the blood-brain barrier (BBB). This study aimed at preparing and characterizing an innovative composite formulation, associating the liposome and hydrogel approaches, suitable for intranasal administration. Thermosensitive gel formulations were obtained based on a mixture of two hydrophilic polymers (Poloxamer 407, P407 and Poloxamer 188, P188) for a controlled delivery through nasal route via liposomes of an active pharmaceutical ingredient (API) of potential interest for Alzheimer's disease. The osmolarity and the gelation temperature (T° sol-gel) of formulations, defined in a ternary diagram, were investigated by rheometry and visual determination. Regarding the issue of assays, a mixture composed of P407/P188 (15/1%, ) was selected for intranasal administration in terms of T° sol-gel and for the compatibility with the olfactory mucosal (280 ± 20 mOsmol, pH 6). Liposomes of API were prepared by the thin film hydration method. Mucoadhesion studies were performed by using mucin disc, and they showed the good natural mucoadhesive characteristics of in situ gel formulations, which increased when liposomes were added. The study demonstrated successful pharmacotechnical development of a promising API-loaded liposomes in a thermosensitive hydrogel intended for nasal Alzheimer's disease treatment

Citing Articles

Evidence from a mouse model supports repurposing an anti-asthmatic drug, bambuterol, against Alzheimer's disease by administration through an intranasal route.

Groo A, Curel T, Malzert-Freon A, Seguy L, Bento O, Corvaisier S Commun Biol. 2025; 8(1):155.

PMID: 39893320 PMC: 11787381. DOI: 10.1038/s42003-025-07599-7.

Long-acting parenteral formulations of hydrophilic drugs, proteins, and peptide therapeutics: mechanisms, challenges, and therapeutic benefits with a focus on technologies.

Nakmode D, Singh B, Abdella S, Song Y, Garg S Drug Deliv Transl Res. 2024; 15(4):1156-1180.

PMID: 39661312 PMC: 11870889. DOI: 10.1007/s13346-024-01747-y.

Development of Nanocomposite Microspheres for Nasal Administration of Deferiprone in Neurodegenerative Disorders.

Boyuklieva R, Katsarov P, Zagorchev P, Abarova S, Hristozova A, Pilicheva B J Funct Biomater. 2024; 15(11).

PMID: 39590533 PMC: 11595062. DOI: 10.3390/jfb15110329.

Hybrid nanostructures for neurodegenerative disease theranostics: the art in the combination of biomembrane and non-biomembrane nanostructures.

Gao C, Xiong R, Zhang Z, Peng H, Gu Y, Xu W Transl Neurodegener. 2024; 13(1):43.

PMID: 39192378 PMC: 11348682. DOI: 10.1186/s40035-024-00436-7.

Formulation of Metoclopramide Hydrochloride-Loaded Lipid Carriers by QbD Approach for Combating Nausea: Safety and Bioavailability Evaluation in New Zealand Rabbit.

Baranauskaite J, Aydin M, Uner B, Tas C AAPS PharmSciTech. 2024; 25(4):73.

PMID: 38575825 DOI: 10.1208/s12249-024-02791-0.

References

Karavasili C, Fatouros D . Smart materials: in situ gel-forming systems for nasal delivery. Drug Discov Today. 2015; 21(1):157-166. DOI: 10.1016/j.drudis.2015.10.016. View

Jogani V, Jinturkar K, Vyas T, Misra A . Recent patents review on intranasal administration for CNS drug delivery. Recent Pat Drug Deliv Formul. 2008; 2(1):25-40. DOI: 10.2174/187221108783331429. View

Soliman G, Fetih G, Abbas A . Thermosensitive bioadhesive gels for the vaginal delivery of sildenafil citrate: in vitro characterization and clinical evaluation in women using clomiphene citrate for induction of ovulation. Drug Dev Ind Pharm. 2016; 43(3):399-408. DOI: 10.1080/03639045.2016.1254239. View

Hallschmid M, Benedict C, Schultes B, Perras B, Fehm H, Kern W . Towards the therapeutic use of intranasal neuropeptide administration in metabolic and cognitive disorders. Regul Pept. 2008; 149(1-3):79-83. DOI: 10.1016/j.regpep.2007.06.012. View

Bonaccorso A, Musumeci T, Serapide M, Pellitteri R, Uchegbu I, Puglisi G . Nose to brain delivery in rats: Effect of surface charge of rhodamine B labeled nanocarriers on brain subregion localization. Colloids Surf B Biointerfaces. 2017; 154:297-306. DOI: 10.1016/j.colsurfb.2017.03.035. View

Al Asmari A, Ullah Z, Tariq M, Fatani A . Preparation, characterization, and in vivo evaluation of intranasally administered liposomal formulation of donepezil. Drug Des Devel Ther. 2016; 10:205-15. PMC: 4716722. DOI: 10.2147/DDDT.S93937. View

Liu Y, Yang F, Feng L, Yang L, Chen L, Wei G . retention of poloxamer-based hydrogels for vaginal application in mouse and rat models. Acta Pharm Sin B. 2017; 7(4):502-509. PMC: 5518644. DOI: 10.1016/j.apsb.2017.03.003. View

Jourdan J, Since M, El Kihel L, Lecoutey C, Corvaisier S, Legay R . Novel benzylidenephenylpyrrolizinones with pleiotropic activities potentially useful in Alzheimer's disease treatment. Eur J Med Chem. 2016; 114:365-79. DOI: 10.1016/j.ejmech.2016.03.023. View

Giuliano E, Paolino D, Fresta M, Cosco D . Mucosal Applications of Poloxamer 407-Based Hydrogels: An Overview. Pharmaceutics. 2018; 10(3). PMC: 6161217. DOI: 10.3390/pharmaceutics10030159. View

10.

Aderibigbe B . In Situ-Based Gels for Nose to Brain Delivery for the Treatment of Neurological Diseases. Pharmaceutics. 2018; 10(2). PMC: 6027251. DOI: 10.3390/pharmaceutics10020040. View

11.

Mourtas S, Fotopoulou S, Duraj S, Sfika V, Tsakiroglou C, Antimisiaris S . Liposomal drugs dispersed in hydrogels. Effect of liposome, drug and gel properties on drug release kinetics. Colloids Surf B Biointerfaces. 2007; 55(2):212-21. DOI: 10.1016/j.colsurfb.2006.12.005. View

12.

Arumugam K, Subramanian G, Mallayasamy S, Averineni R, Reddy M, Udupa N . A study of rivastigmine liposomes for delivery into the brain through intranasal route. Acta Pharm. 2008; 58(3):287-97. DOI: 10.2478/v10007-008-0014-3. View

13.

Morrison E, Costanzo R . Morphology of the human olfactory epithelium. J Comp Neurol. 1990; 297(1):1-13. DOI: 10.1002/cne.902970102. View

14.

Mayer L, Tai L, Ko D, Masin D, GINSBERG R, Cullis P . Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. Cancer Res. 1989; 49(21):5922-30. View

15.

Greig N, Lahiri D, Sambamurti K . Butyrylcholinesterase: an important new target in Alzheimer's disease therapy. Int Psychogeriatr. 2003; 14 Suppl 1:77-91. DOI: 10.1017/s1041610203008676. View

16.

. 2016 Alzheimer's disease facts and figures. Alzheimers Dement. 2016; 12(4):459-509. DOI: 10.1016/j.jalz.2016.03.001. View

17.

Darvesh S, Hopkins D, Geula C . Neurobiology of butyrylcholinesterase. Nat Rev Neurosci. 2003; 4(2):131-8. DOI: 10.1038/nrn1035. View

18.

Bangham A, Standish M, Watkins J . Diffusion of univalent ions across the lamellae of swollen phospholipids. J Mol Biol. 1965; 13(1):238-52. DOI: 10.1016/s0022-2836(65)80093-6. View

19.

Ganger S, Schindowski K . Tailoring Formulations for Intranasal Nose-to-Brain Delivery: A Review on Architecture, Physico-Chemical Characteristics and Mucociliary Clearance of the Nasal Olfactory Mucosa. Pharmaceutics. 2018; 10(3). PMC: 6161189. DOI: 10.3390/pharmaceutics10030116. View

20.

Tian J, Ke X, Chen Z, Wang C, Zhang Y, Zhong T . Melittin liposomes surface modified with poloxamer 188: in vitro characterization and in vivo evaluation. Pharmazie. 2011; 66(5):362-7. View